Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2020

02.07.2020

Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis

verfasst von: Peter Ip Fung Chun, Heather Lehman

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Atopic dermatitis is a common immunologic skin disease. Mild atopic dermatitis can be managed with emollients and topical therapies such as low potency topical steroids, which have a favorable safety profile. Severe atopic dermatitis, in contrast, is a challenging disease to treat. Topical therapies are typically inadequate for control of severe atopic dermatitis. When topical therapies fail, the mainstay of therapy for severe atopic dermatitis has traditionally been phototherapy or off-label use of systemic immunosuppressant treatment, yet systemic immunosuppressants all have significant potential toxicities, drug interactions, and contraindications, requiring close monitoring. Targeted biologics are therefore attractive treatment options for topical therapy-refractory cases of atopic dermatitis, with the potential to offer effective, safer treatment of uncontrolled atopic dermatitis. Dupilumab, as the only biologic therapy currently FDA-approved for atopic dermatitis, is effective for many patients, but there is need for continuing study of additional biologic therapies to address the needs of diverse patients with uncontrolled atopic dermatitis.
Literatur
1.
Silverberg JI, Simpson EL (2014) Associations of childhood eczema severity: a US population-based study. Dermatitis 25(3):107–114PubMedPubMedCentral
2.
Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group (2007) A population-based survey of eczema prevalence in the United States. Dermatitis 18(2):82–91PubMed
3.
Shaw TE, Currie GP, Koudelka CW, Simpson EL (2011) Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol 131(1):67–73PubMed
4.
Silverberg JI, Hanifin JM (2013) Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 132(5):1132–1138PubMed
5.
Patrizi A, Raone B, Ravaioli GM (2015) Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol 8:511–520PubMedPubMedCentral
6.
Hamid Q, Boguniewicz M, Leung DY (1994) Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94(2):870–876PubMedPubMedCentral
7.
Jeong CW, Ahn KS, Rho NK, Park YD, Lee DY, Lee JH, Lee ES, Yang JM (2003) Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp Allergy 33(12):1717–1724PubMed
8.
He JQ, Chan-Yeung M, Becker AB, Dimich-Ward H, Ferguson AC, Manfreda J, Watson WTA, Sandford AJ (2003) Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children. Genes Immun 4(5):385–389PubMed
9.
Namkung JH, Lee JE, Kim E, Kim HJ, Seo EY, Jang HY, Shin ES, Cho EY, Yang JM (2011) Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population. Exp Dermatol 20(11):915–919PubMed
10.
Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQF, Mitsui H, Cardinale I, de Guzman Strong C, Krueger JG, Guttman-Yassky E (2012) Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130(6):1344–1354PubMedPubMedCentral
11.
Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, Dutt R, Fuentes-Duculan J, Zheng X, Li X, Bonifacio KM, Kunjravia N, Coats I, Cueto I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E (2017) Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 26(1):28–35PubMed
12.
Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, Yancopoulos GD, Pirozzi G, Guttman-Yassky E (2014) Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134(6):1293–1300PubMed
13.
Masuda K, Katoh N, Okuda F, Kishimoto S (2003) Increased levels of serum interleukin-16 in adult type atopic dermatitis. Acta Derm Venereol 83(4):249–253PubMed
14.
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF, American Academy of Dermatology (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71(2):327–349PubMedPubMedCentral
15.
Morison WL, Parrish J, Fitzpatrick TB (1978) Oral psoralen photochemotherapy of atopic eczema. Br J Dermatol 98(1):25–30PubMed
16.
Meduri NB, Vandergriff T, Rasmussen H, Jacobe H (2007) Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed 23(4):106–112PubMed
17.
Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13(4):136–142PubMed
18.
van Joost T et al (1994) Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 130(5):634–640PubMed
19.
Meggitt SJ, Gray JC, Reynolds NJ (2006) Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 367(9513):839–846PubMed
20.
Schram ME et al (2012) Methotrexate versus azathioprine in severe atopic dermatitis. Ned Tijdschr Dermatol Venereol 22(3):176–178
21.
Murray ML, Cohen JB (2007) Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 32(1):23–27PubMed
22.
Paller AS et al (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75(3):494–503.e6PubMed
23.
Lacombe Barrios J, Bégin P, Paradis L, Hatami A, Paradis J, Des Roches A (2013) Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol 69(5):832–834PubMed
24.
Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54(1):68–72PubMed
25.
Ramirez del Pozo ME et al (2011) Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 21(5):416–417PubMed
26.
Sheinkopf LE, Rafi AW, Do LAT, Katz RM, Klaustermeyer WB (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29(5):530–537PubMed
27.
Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168–170PubMed
28.
Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162(1):89–93PubMed
29.
Heil PM, Maurer D, Klein B, Hultsch T, Stingl G (2010) Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8(12):990–998PubMed
30.
Identifier NCT01552629. A study evaluating the safety and efficacy of QGE031 in atopic dermatitis patients. National Library of Medicine: ClinicalTrials.gov .
31.
Jacobi A, Antoni C, Manger B, Schuler G, Hertl M (2005) Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52(3 Pt 1):522–526PubMed
32.
Cassano N, Loconsole F, Coviello C, Vena GA (2006) Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 19(1):237–240PubMed
33.
Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S (2005) Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 53(2):358–359PubMed
34.
Rullan P, Murase J (2009) Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J Drugs Dermatol 8(9):873–876PubMed
35.
Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU (2008) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121(1):122–128PubMed
36.
Sediva A et al (2008) Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 121(6):1515–1516 author reply 1516-7PubMed
37.
McDonald BS, Jones J, Rustin M (2016) Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients. Clin Exp Dermatol 41(1):45–47PubMed
38.
Leiferman KM (2001) A role for eosinophils in atopic dermatitis. J Am Acad Dermatol 45(1 Suppl):S21–S24PubMed
39.
Taniuchi S, Chihara J, Kojima T, Yamamoto A, Sasai M, Kobayashi Y (2001) Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci 26(1):79–82PubMed
40.
Halmerbauer G, Frischer T, Koller DY (1997) Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 52(7):765–769PubMed
41.
Pucci N, Lombardi E, Novembre E, Farina S, Bernardini R, Rossi E, Favilli T, Vierucci A (2000) Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 105(2 Pt 1):353–357PubMed
42.
Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plotz S, Knol EF, Kapp A, Bruijnzeel-Koomen CAFM, Ring J, Bruin-Weller MS (2005) Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60(5):693–696PubMed
43.
Identifier NCT03055195. Efficacy and safety study of mepolizumab in subjects with moderate to severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov .
44.
Tazawa T, Sugiura H, Sugiura Y, Uehara M (2004) Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res 295(11):459–464PubMed
45.
Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, Krueger JG, Suarez-Farinas M, Guttman-Yassky E (2017) An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol 137(3):603–613PubMed
46.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M, SOLO 1 and SOLO 2 Investigators (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348PubMed
47.
Treister AD, Kraff-Cooper C, Lio PA (2018) Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 154(10):1208–1211PubMedPubMedCentral
48.
Akinlade B, Guttman-Yassky E, Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A (2019) Conjunctivitis in dupilumab clinical trials. Br J Dermatol 181
49.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HCH, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287–2303PubMed
50.
Dupixent (dupilumab) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2020
51.
Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J (2018) Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol 17(7):750–756PubMed
52.
Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LMK, Kemp B, Spooner J, Keen J, Minter R, Uddin F, Colice G, Wilkinson T, Vaughan T, May RD (2017) Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol 429(2):208–219PubMed
53.
Wollenberg A et al (2018) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol
54.
Identifier NCT03131648. Tralokinumab monotherapy for moderate to severe atopic dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1). National Library of Medicine: ClinicalTrials.gov .
55.
dentifier NCT03160885. Tralokinumab monotherapy for moderate to severe atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2). National Library of Medicine: ClinicalTrials.gov .
56.
Identifier NCT03363854. Tralokinumab in combination with topical corticosteroids for moderate to severe atopic dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3). National Library of Medicine: ClinicalTrials.gov .
57.
Ultsch M, Bevers J, Nakamura G, Vandlen R, Kelley RF, Wu LC, Eigenbrot C (2013) Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol 425(8):1330–1339PubMed
58.
Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, Owen R, Putnam W, Castro M, DeBusk K, Lin CY, Voulgari A, Yen K, Omachi TA (2018) Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78(5):863–871 e11PubMed
59.
Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL (2020) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatology 156(4):411–420PubMedCentralPubMed
60.
Identifier NCT04146363. Evaluation of the efficacy and safety of lebrikizumab in moderate to severe atopic dermatitis (ADvocate1). National Library of Medicine: ClinicalTrials.gov .
61.
Identifier NCT04178967. Evaluation of the efficacy and safety of lebrikizumab in moderate to severe atopic dermatitis (ADvocate2). National Library of Medicine: ClinicalTrials.gov .
62.
Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, Waal-Malefyt R, Bazan F, Kastelein RA, Liu YJ (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3(7):673–680PubMed
63.
Ebner S, Nguyen VA, Forstner M, Wang YH, Wolfram D, Liu YJ, Romani N (2007) Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 119(4):982–990PubMed
64.
Wilson SR, Thé L, Batia LM, Beattie K, Katibah GE, McClain SP, Pellegrino M, Estandian DM, Bautista DM (2013) The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155(2):285–295PubMedPubMedCentral
65.
Han H, Thelen TD, Comeau MR, Ziegler SF (2014) Thymic stromal lymphopoietin-mediated epicutaneous inflammation promotes acute diarrhea and anaphylaxis. J Clin Invest 124(12):5442–5452PubMedPubMedCentral
66.
Moniaga CS, Jeong SK, Egawa G, Nakajima S, Hara-Chikuma M, Jeon JE, Lee SH, Hibino T, Miyachi Y, Kabashima K (2013) Protease activity enhances production of thymic stromal lymphopoietin and basophil accumulation in flaky tail mice. Am J Pathol 182(3):841–851PubMed
67.
Identifier NCT02525094. Phase 2a study to evaluate the efficacy and safety of MEDI9929 in adults with atopic dermatitis (ALLEVIAD). National Library of Medicine: ClinicalTrials.gov .
68.
Identifier NCT03809663. A dose ranging placebo-controlled double-blind study to evaluate the safety and efficacy of tezepelumab in atopic dermatitis. National Library of Medicine: ClinicalTrials.gov .
69.
Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, Peng X, Wen HC, Govas P, Gudi G, CA V, Fang H, Salhi Y, Back J, Reddy V, Bissonnette R, Maari C, Grossman F, Wolff G (2019) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 144(2):482–493 e7PubMed
70.
Identifier NCT03568162. Phase 2b study to evaluate the efficacy and safety of ISB 830 in adults with moderate to severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov .
71.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG (2018) Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol 78(5):872–881 e6PubMedPubMedCentral
72.
Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A, Kukova G, Buhl T, Ikoma A, Buddenkotte J, Soumelis V, Feld M, Alenius H, Dillon SR, Carstens E, Homey B, Basbaum A, Steinhoff M (2014) A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 133(2):448–460PubMed
73.
Hanel KH et al (2016) Control of the physical and antimicrobial skin barrier by an IL-31-IL-1 signaling network. J Immunol 196(8):3233–3244PubMed
74.
Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, Galus R, Etoh T, Mihara R, Yoshida H, Stewart J, Kabashima K, XCIMA Study Group (2017) Anti-interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 376(9):826–835PubMed
75.
Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, Etoh T, Mihara R, Nakano M, Ruzicka T (2018) Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol 142:1121–1130.e7PubMed
76.
Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, Murrell DF, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A (2020) Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 145(1):173–182PubMed
77.
Identifier NCT03985943. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov .
78.
Identifier NCT03989206. Long-term safety and efficacy of nemolizumab with moderate-to-severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov .
79.
Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, Peng X, Estrada YD, Nakajima S, Honda T, Shin JU, Lee H, Krueger JG, Lee KH, Kabashima K, Guttman-Yassky E (2015) The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 136(5):1254–1264PubMed
80.
Saeki H, Kabashima K, Tokura Y, Murata Y, Shiraishi A, Tamamura R, Randazzo B, Imanaka K (2017) Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 177(2):419–427PubMed
81.
Identifier NCT03706040. A study to evaluate risankizumab in adult and adolescent subjects with moderate to severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov .
82.
Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, Chamlin SL, Cohen DE, Cordoro KM, Davis DM, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Simpson EL, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Eichenfield LF (2014) Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol 71(6):1218–1233PubMedPubMedCentral
83.
Schneider L et al (2013) Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 131(2):295–9 e1–27PubMed
Metadaten
Titel
Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis
verfasst von
Peter Ip Fung Chun
Heather Lehman
Publikationsdatum
02.07.2020
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2020
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-020-08802-9

Weitere Artikel der Ausgabe 2/2020

Clinical Reviews in Allergy & Immunology 2/2020 Zur Ausgabe

ReviewPaper

Eosinophilic Esophagitis: the Potential Role of Biologics in its Treatment

ReviewPaper

Asthma Phenotypes as a Guide for Current and Future Biologic Therapies

ReviewPaper

Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends

ReviewPaper

The Current State of Biologic Therapies for Treatment of Refractory Asthma

ReviewPaper

Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases

Correction

Correction to: Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise